

Resource Summary Report

Generated by [dkNET](#) on Aug 13, 2026

Clinical and Laboratory Standards Institute

RRID:SCR_002382

Type: Tool

Proper Citation

Clinical and Laboratory Standards Institute (RRID:SCR_002382)

Resource Information

URL: <http://www.clsi.org/>

Proper Citation: Clinical and Laboratory Standards Institute (RRID:SCR_002382)

Description: A not-for-profit membership organization that brings together the global laboratory community to foster excellence in laboratory medicine by facilitating the development of clinical laboratory testing standards based on input from and consensus among industry, government, and health care professionals. CLSI is setting the standard for quality in clinical laboratory testing around the world.

Abbreviations: CLSI

Resource Type: data or information resource, narrative resource, standard specification, knowledge environment

Keywords: clinical, laboratory testing, quality, clinical laboratory testing standard, laboratory, testing

Availability: Membership fee

Resource Name: Clinical and Laboratory Standards Institute

Resource ID: SCR_002382

Alternate IDs: OMICS_01777

Record Creation Time: 20220129T080213+0000

Record Last Update: 20260813T054835+0000

Ratings and Alerts

No rating or validation information has been found for Clinical and Laboratory Standards Institute.

No alerts have been found for Clinical and Laboratory Standards Institute.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 195 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Draveny M, et al. (2026) NV716 acts as an envelope-active adjuvant that enhances antibiotic accumulation in *Pseudomonas aeruginosa*. *npj antimicrobials and resistance*, 4(1).

Vidyashankar R, et al. (2026) A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis. *Frontiers in veterinary science*, 13, 1727080.

Juzbašić T, et al. (2026) Extensively drug-resistant (XDR) *Neisseria gonorrhoeae* cured with ceftriaxone 2 g intravenous monotherapy in Croatia, March 2026. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*, 31(21).

Jacobsson S, et al. (2026) High prevalence of tetracycline resistance in *Neisseria gonorrhoeae* across 22 European countries, 2024. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*, 31(2).

Ahlstrand J, et al. (2026) High in vitro activity of the novel antimicrobial gepotidacin against *Neisseria gonorrhoeae* isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24. *The Journal of antimicrobial chemotherapy*, 81(1).

Xu J, et al. (2026) Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024. *Antimicrobial agents and chemotherapy*, 70(7), e0003126.

Haseeb U, et al. (2025) Molecular Characterization of KPC-2 and CMY AmpC Beta Lactamases in Ceftazidime-Avibactam Resistant *Klebsiella pneumoniae* in a Tertiary Care Hospital. *Cureus*, 17(10), e95576.

Deng S, et al. (2025) Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China. *BMC infectious diseases*, 25(1), 110.

Liu X, et al. (2025) First report of a carbapenem-resistant *Serratia sarumanii* clinical strain co-harboring bla KPC-2 and bla NDM-1 genes in China. *Current research in microbial sciences*, 9, 100411.

Wasilewska A, et al. (2025) Apple Extract as an Effective Silver Reducer in the Synthesis of Ag Nanoparticles. *Nanomaterials (Basel, Switzerland)*, 15(8).

Zhang C, et al. (2025) Emergence, evolution and temporal spread of ceftriaxone-resistant *Neisseria gonorrhoeae* in China from 2002 to 2022: a retrospective genomic surveillance study. *Emerging microbes & infections*, 14(1), 2579397.

Miernyk KM, et al. (2025) Successful Transition to Whole-Genome Sequencing and Bioinformatics to Identify Invasive *Streptococcus* spp. Drug Resistance, Alaska, USA. *Emerging infectious diseases*, 31(13), 103.

Lu J, et al. (2025) Identification of a novel aminoglycoside nucleotidyltransferase gene in *Morganella morganii* from farm sewage. *BMC microbiology*, 25(1), 161.

Shirshikova TV, et al. (2025) *Nocardia mangyaensis* NH1: A Biofertilizer Candidate with Tolerance to Pesticides, Heavy Metals and Antibiotics. *Microorganisms*, 13(12).

Do K, et al. (2025) Tetracycline-resistant *Neisseria gonorrhoeae* global estimates-impacts on doxycycline post-exposure prophylaxis implementation and monitoring: a systematic review. *JAC-antimicrobial resistance*, 7(4), dlaf120.

Huang Z, et al. (2025) Epidemiological and comparative genomic analysis of pathogenic *Glaesserella parasuis* from livestock agriculture in Shandong, China. *Frontiers in microbiology*, 16, 1698342.

, et al. (2025) Guidance on the characterisation of microorganisms in support of the risk assessment of products used in the food chain. *EFSA journal. European Food Safety Authority*, 23(11), e9705.

Castro MG, et al. (2025) Effectiveness of infection control measures informed by a modified Blue-Carba test in reducing rectal carriage of carbapenemase-producing bacteria in general wards: a prospective interrupted time series study. *Frontiers in pharmacology*, 16, 1584646.

Schuetz AN, et al. (2025) Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. *Journal of clinical microbiology*, 63(9), e0162323.

Xie J, et al. (2025) Antibiotic resistance of *Helicobacter pylori* and related risk factors in Hunan Province: A multicenter study. *World journal of gastroenterology*, 31(12), 104835.